Cargando…
The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma
INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), de...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814178/ https://www.ncbi.nlm.nih.gov/pubmed/29464038 http://dx.doi.org/10.18632/oncotarget.23533 |
_version_ | 1783300295355269120 |
---|---|
author | Ziebart, Andreas Huber, Ulrich Jeske, Sandra Laban, Simon Doescher, Johannes Hoffmann, Thomas K. Brunner, Cornelia Jackson, Edwin K. Schuler, Patrick J. |
author_facet | Ziebart, Andreas Huber, Ulrich Jeske, Sandra Laban, Simon Doescher, Johannes Hoffmann, Thomas K. Brunner, Cornelia Jackson, Edwin K. Schuler, Patrick J. |
author_sort | Ziebart, Andreas |
collection | PubMed |
description | INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), defined as CD19(+)CD39(+)CD73(+) B cells, play a significant role in the production of immunosuppressive, extracellular adenosine (ADO). Here, we tested the influence of chemotherapy on Breg function. RESULTS: In HNSCC patients, Breg were diminished in absolute number and frequency after chemotherapy (paired samples). Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO. These findings were confirmed in a second patient cohort. Surface expression of CD39 correlated strongly with the production of ADO as measured by mass spectrometry. CONCLUSIONS: Platinum-based anti-tumor-therapy reduces the number of adenosine-producing B cells and, consequently, potential immunosuppression within the tumor environment. Breg function in terms of ADO production and their potential capacity to suppress CD4(+) T cells are promoted by methotrexate treatment amplifying anti-inflammatory therapeutic effects. Our results add to the understanding of how chemotherapeutic drugs can influence the human immune system and may therefore help to orchestrate standard oncologic therapy with new immune modulating approaches. METHODS: Mononuclear cells were collected prospectively from HNSCC patients before and after chemotherapy (n = 18), from healthy donors (n = 20), and an additional cohort sampled several months after chemotherapy (n = 14). Frequency, phenotype, and function of Breg were determined by multicolor flow cytometry, ATP luminescence assay as well as mass spectrometry measuring 5′-AMP, ADO, and inosine. Isolated B cells were incubated with chemotherapeutic drugs (cisplatin, methotrexate, paclitaxel, 5-fluorouracil) in vitro for functional studies. |
format | Online Article Text |
id | pubmed-5814178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58141782018-02-20 The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma Ziebart, Andreas Huber, Ulrich Jeske, Sandra Laban, Simon Doescher, Johannes Hoffmann, Thomas K. Brunner, Cornelia Jackson, Edwin K. Schuler, Patrick J. Oncotarget Research Paper INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), defined as CD19(+)CD39(+)CD73(+) B cells, play a significant role in the production of immunosuppressive, extracellular adenosine (ADO). Here, we tested the influence of chemotherapy on Breg function. RESULTS: In HNSCC patients, Breg were diminished in absolute number and frequency after chemotherapy (paired samples). Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO. These findings were confirmed in a second patient cohort. Surface expression of CD39 correlated strongly with the production of ADO as measured by mass spectrometry. CONCLUSIONS: Platinum-based anti-tumor-therapy reduces the number of adenosine-producing B cells and, consequently, potential immunosuppression within the tumor environment. Breg function in terms of ADO production and their potential capacity to suppress CD4(+) T cells are promoted by methotrexate treatment amplifying anti-inflammatory therapeutic effects. Our results add to the understanding of how chemotherapeutic drugs can influence the human immune system and may therefore help to orchestrate standard oncologic therapy with new immune modulating approaches. METHODS: Mononuclear cells were collected prospectively from HNSCC patients before and after chemotherapy (n = 18), from healthy donors (n = 20), and an additional cohort sampled several months after chemotherapy (n = 14). Frequency, phenotype, and function of Breg were determined by multicolor flow cytometry, ATP luminescence assay as well as mass spectrometry measuring 5′-AMP, ADO, and inosine. Isolated B cells were incubated with chemotherapeutic drugs (cisplatin, methotrexate, paclitaxel, 5-fluorouracil) in vitro for functional studies. Impact Journals LLC 2017-12-20 /pmc/articles/PMC5814178/ /pubmed/29464038 http://dx.doi.org/10.18632/oncotarget.23533 Text en Copyright: © 2018 Ziebart et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Ziebart, Andreas Huber, Ulrich Jeske, Sandra Laban, Simon Doescher, Johannes Hoffmann, Thomas K. Brunner, Cornelia Jackson, Edwin K. Schuler, Patrick J. The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title_full | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title_fullStr | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title_full_unstemmed | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title_short | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
title_sort | influence of chemotherapy on adenosine-producing b cells in patients with head and neck squamous cell carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814178/ https://www.ncbi.nlm.nih.gov/pubmed/29464038 http://dx.doi.org/10.18632/oncotarget.23533 |
work_keys_str_mv | AT ziebartandreas theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT huberulrich theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT jeskesandra theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT labansimon theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT doescherjohannes theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT hoffmannthomask theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT brunnercornelia theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT jacksonedwink theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT schulerpatrickj theinfluenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT ziebartandreas influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT huberulrich influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT jeskesandra influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT labansimon influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT doescherjohannes influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT hoffmannthomask influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT brunnercornelia influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT jacksonedwink influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma AT schulerpatrickj influenceofchemotherapyonadenosineproducingbcellsinpatientswithheadandnecksquamouscellcarcinoma |